Advancements in endometrial treatment – HUTCHMED & Innovent’s cancer combo NDA accepted with Priority Review

In an important announcement today (April 2), HUTCHMED and Innovent jointly revealed the acceptance of their New Drug Application (NDA) in China for the combination of Fruquintinib with Sintilimab.